MRK•benzinga•
Merck Announces Results From Dose Confirmation Portion Of Phase 2 waveLINE-003 Trial Trial Of Zilovertamab Vedotin Plus Standard of Care; Zilovertamab Vedotin Plus R-GemOx Achieved 56.3% Objective Response Rate In Patients With Relapsed/Refractory DLBCL
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 30, 2025 by benzinga